Infinity Pharmaceuticals Overview
- Year Founded
-
1995
- Status
-
Acquired/Merged
- Employees
-
30
- Latest Deal Type
-
M&A
Infinity Pharmaceuticals General Information
Description
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company dedicated to developing novel medicines for people with cancer. It combines scientific expertise with a passion for developing novel small molecule drugs that target disease pathways for potential applications in oncology. It is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma.
Contact Information
Website
www.infi.comCorporate Office
- 1100 Massachusetts Avenue
- Cambridge, MA 02138
- United States
Corporate Office
- 1100 Massachusetts Avenue
- Cambridge, MA 02138
- United States
Infinity Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Merger/Acquisition | 01-Feb-2024 | Completed | Generating Revenue/Not Profitable | |||
| 12. Bankruptcy: Admin/Reorg | 02-Oct-2023 | Completed | Bankruptcy: Admin/Reorg | |||
| 11. Merger/Acquisition | 23-Feb-2023 | Cancelled | Generating Revenue | |||
| 10. 2PO | 29-Sep-2017 | Completed | Generating Revenue | |||
| 9. PIPE | 04-Apr-2017 | Completed | Generating Revenue | |||
| 8. Merger/Acquisition | 03-Sep-2014 | Cancelled | Generating Revenue | |||
| 7. 2PO | 21-Sep-2012 | Completed | Generating Revenue | |||
| 6. PIPE | 01-Jul-2012 | Completed | Generating Revenue | |||
| 5. Reverse Merger | 13-Sep-2006 | $120M | Completed | Generating Revenue | ||
| 4. Later Stage VC (Series C) | 23-Dec-2004 | $50M | $120M | Completed | Generating Revenue |
Infinity Pharmaceuticals Comparisons
Industry
Financing
Details
Infinity Pharmaceuticals Competitors (44)
One of Infinity Pharmaceuticals’s 44 competitors is Sharp Therapeutics (Biotechnology), a Formerly VC-backed company based in Pittsburgh, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sharp Therapeutics (Biotechnology) | Formerly VC-backed | Pittsburgh, PA | ||||
| Precigen | Formerly VC-backed | Germantown, MD | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| BioNTech | Formerly VC-backed | Mainz, Germany | ||||
| XBiotech | Corporation | Austin, TX |
Infinity Pharmaceuticals Patents
Infinity Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022125497-A1 | Eganelisib for use in the treatment of pd-l1 negative cancer | Inactive | 08-Dec-2020 | ||
| AU-2017281797-A1 | Combination therapies | Inactive | 24-Jun-2016 | ||
| CA-3028718-A1 | Combination therapies | Pending | 24-Jun-2016 | ||
| EP-3474856-A1 | Combination therapies | Active | 24-Jun-2016 | ||
| EP-3474856-B1 | Combination therapies | Active | 24-Jun-2016 | A61K39/395 |
Infinity Pharmaceuticals Signals
Infinity Pharmaceuticals Former Investors (25)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advent Life Sciences | Venture Capital | Minority | ||
| Advent Venture Partners | Venture Capital | Minority | ||
| Aisling Capital | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Amgen Ventures | Corporate Venture Capital | Minority |
Infinity Pharmaceuticals Acquisitions (1)
Infinity Pharmaceuticals’s most recent deal was a Merger/Acquisition with Discovery Partners International. The deal was made on 12-Sep-2006.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Discovery Partners International | 12-Sep-2006 | Merger/Acquisition | Drug Discovery |
Infinity Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Infinity Pharmaceuticals FAQs
-
When was Infinity Pharmaceuticals founded?
Infinity Pharmaceuticals was founded in 1995.
-
Where is Infinity Pharmaceuticals headquartered?
Infinity Pharmaceuticals is headquartered in Cambridge, MA.
-
What is the size of Infinity Pharmaceuticals?
Infinity Pharmaceuticals has 30 total employees.
-
What industry is Infinity Pharmaceuticals in?
Infinity Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Infinity Pharmaceuticals a private or public company?
Infinity Pharmaceuticals is a Private company.
-
What is Infinity Pharmaceuticals’s current revenue?
The current revenue for Infinity Pharmaceuticals is .
-
How much funding has Infinity Pharmaceuticals raised over time?
Infinity Pharmaceuticals has raised $150M.
-
Who are Infinity Pharmaceuticals’s investors?
Advent Life Sciences, Advent Venture Partners, Aisling Capital, Alexandria Venture Investments, and Amgen Ventures are 5 of 25 investors who have invested in Infinity Pharmaceuticals.
-
Who are Infinity Pharmaceuticals’s competitors?
Sharp Therapeutics (Biotechnology), Precigen, Sangamo Therapeutics, BioNTech, and XBiotech are some of the 44 competitors of Infinity Pharmaceuticals.
-
When was Infinity Pharmaceuticals acquired?
Infinity Pharmaceuticals was acquired on 01-Feb-2024.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process